Compare COGT & HOMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COGT | HOMB |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | 2552 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.6B |
| IPO Year | 2018 | 2006 |
| Metric | COGT | HOMB |
|---|---|---|
| Price | $39.53 | $28.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 5 |
| Target Price | $28.08 | ★ $32.40 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 11-03-2025 | 01-14-2026 |
| Dividend Yield | N/A | ★ 2.93% |
| EPS Growth | N/A | ★ 18.95 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $1,042,417,000.00 |
| Revenue This Year | N/A | $13.21 |
| Revenue Next Year | N/A | $3.01 |
| P/E Ratio | ★ N/A | $12.48 |
| Revenue Growth | N/A | ★ 7.75 |
| 52 Week Low | $3.72 | $24.22 |
| 52 Week High | $43.73 | $31.27 |
| Indicator | COGT | HOMB |
|---|---|---|
| Relative Strength Index (RSI) | 64.24 | 60.37 |
| Support Level | $37.86 | $28.53 |
| Resistance Level | $42.25 | $29.05 |
| Average True Range (ATR) | 2.10 | 0.51 |
| MACD | -0.73 | 0.05 |
| Stochastic Oscillator | 29.68 | 81.13 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.